Results 171 to 180 of about 6,510 (202)

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

Clinical Infectious Diseases, 2023
Julie Boucau, Rockib Uddin, James Regan
exaly  

Dexamethasone/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study

Journal of Medical Virology, 2023
Guangtong Deng, Furong Zeng, Pinhua Pan
exaly  

Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study

Lancet Infectious Diseases, The, 2023
Tellen Bennett, David A Mayer, Seth Russell   +2 more
exaly  

Nirmatrelvir+ritonavir/tozinameran

Reactions Weekly, 2022
openaire   +1 more source

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

EClinicalMedicine, 2023
Jon Salmanton-García, Francesco Marchesi, Francesca Farina   +2 more
exaly  

Ciclosporin/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019

Clinical Infectious Diseases, 2023
Sarju Ganatra
exaly  

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System

Annals of Internal Medicine, 2023
Scott Dryden-Peterson, Andy Kim, Arthur Kim   +2 more
exaly  

Immunosuppressants/nirmatrelvir+ritonavir

Reactions Weekly, 2022
openaire   +1 more source